While the variant we describe was not identified in population or disease‐specific databases, the breakpoint assay could be used to screen cohorts of RB1‐mutation negative retinoblastoma patients to establish the precise prevalence of the mutation. This evidence concerns the gene RB1 and retinoblastoma.